New treatment for aggressive brain cancer glioblastoma
MT-125 for the Therapeutic Treatment of Glioblastoma
['FUNDING_OTHER'] · MYOSIN THERAPEUTICS INC. · NIH-11012345
This study is testing a new treatment called MT-125 for glioblastoma, a tough type of brain cancer, to see if it can help stop the cancer from growing and spreading, with the hope of improving survival for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MYOSIN THERAPEUTICS INC. (nih funded) |
| Locations | 1 site (JUPITER, UNITED STATES) |
| Trial ID | NIH-11012345 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new therapeutic agent, MT-125, for treating glioblastoma, a highly aggressive brain cancer. The approach involves using a dual small molecule inhibitor that targets specific molecular motors responsible for tumor growth and invasion. By blocking both the proliferation and invasion of glioblastoma cells, MT-125 aims to improve patient survival rates beyond the current standard of care. The research includes preclinical studies to assess the safety and effectiveness of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who have not responded adequately to existing treatments.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly extend survival and improve quality of life for patients with glioblastoma.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways in glioblastoma, but this specific approach with MT-125 is novel.
Where this research is happening
JUPITER, UNITED STATES
- MYOSIN THERAPEUTICS INC. — JUPITER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROSENFELD, STEVEN S — MYOSIN THERAPEUTICS INC.
- Study coordinator: ROSENFELD, STEVEN S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.